

5. REFERENCES

Alberts, D.S., Hallum, A.V., 3rd, Stratton-Custis, M., Garcia, D.J., Gleason-Guzman, M., Salmon, S.E., Santabarbara, P., Niesor, E.J., Floret, S. and Bentzen, C.L., (2001)

Phase I pharmacokinetic trial and correlative *in vitro* phase II tumor kinetic study of Apomine (SR-45023A), a novel oral bisphosphonate anticancer drug. *Clin Cancer Res*, **7**: 1246-50.

Ali, S.M., Esteva, F.J., Hortobagyi, G., Harvey, H., Seaman, J., Knight, R., Costa, L. and Lipton, A., (2001)

Safety and efficacy of bisphosphonates beyond 24 months in cancer patients. *J Clin Oncol*, **19**: 3434-7.

Amin, D., Cornell, S.A., Gustafson, S.K., Needle, S.J., Ullrich, J.W., Bilder, G.E. and Perrone, M.H., (1992)

Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis. *J Lipid Res*, **33**: 1657-63.

Aparicio, A., Gardner, A., Tu, Y., Savage, A., Berenson, J. and Lichtenstein, A., (1998)

In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. *Leukemia*, **12**: 220-9.

Aznar, S. and Lacal, J.C., (2001)

Rho signals to cell growth and apoptosis. *Cancer Lett*, **165**: 1-10.

Balch, C.M., Buzaid, A.C., Soong, S.J., Atkins, M.B., Cascinelli, N., Coit, D.G., Fleming, I.D., Gershenwald, J.E., Houghton, A., Jr., Kirkwood, J.M., McMasters, K.M., Mihm, M.F., Morton, D.L., Reintgen, D.S., Ross, M.I., Sober, A., Thompson, J.A. and Thompson, J.F., (2001)

Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. *J Clin Oncol*, **19**: 3635-48.

Bar-Sagi, D. and Hall, A., (2000)

Ras and Rho GTPases: a family reunion. *Cell*, **103**: 227-38.

Becker, J.C., Kampgen, E. and Brocker, E., (2000)

Classical chemotherapy for metastatic melanoma. *Clin Exp Dermatol*, **25**: 503-8.

Benford, H.L., Frith, J.C., Auriola, S., Monkkonen, J. and Rogers, M.J., (1999)

Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs. *Mol Pharmacol*, **56**: 131-40.

Benford, H.L., McGowan, N.W., Helfrich, M.H., Nuttall, M.E. and Rogers, M.J., (2001)

Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts *in vitro*. *Bone*, **28**: 465-73.

Berenson, J.R., (2001)

Zoledronic acid in cancer patients with bone metastases: results of Phase I and II trials. *Semin Oncol*, **28**: 25-34.

Berenson, J.R., Rosen, L., Vescio, R., Lau, H.S., Woo, M., Sioufi, A., Kowalski, M.O., Knight, R.D. and Seaman, J.J., (1997)

Pharmacokinetics of pamidronate disodium in patients with cancer with normal or impaired renal function. *J Clin Pharmacol*, **37**: 285-90.

Bergstrom, J.D., Bostedor, R.G., Masarachia, P.J., Reszka, A.A. and Rodan, G., (2000)

Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. *Arch Biochem Biophys*, **373**: 231-41.

Body, J.J., (2001)

Dosing regimens and main adverse events of bisphosphonates. *Semin Oncol*, **28**: 49-53.

Boise, L.H., Gonzalez-Garcia, M., Postema, C.E., Ding, L., Lindsten, T., Turka, L.A., Mao, X., Nunez, G. and Thompson, C.B., (1993)

bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. *Cell*, **74**: 597-608.

Boissier, S., Ferreras, M., Peyruchaud, O., Marnett, S., Ebetino, F.H., Colombel, M., Delmas, P., Delaisse, J.M. and Clezardin, P., (2000)

Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. *Cancer Res*, **60**: 2949-54.

Boissier, S., Marnett, S., Frappart, L., Cuzin, B., Ebetino, F.H., Delmas, P.D. and Clezardin, P., (1997)

Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. *Cancer Res*, **57**: 3890-4.

Braun-Falco, O., Plewig, G., Wolff, H.H. and Winkelmann, R.K., (1992)

Dermatology (3rd edition) *Springer, Berlin*

Cheer, S.M. and Noble, S., (2001)

Zoledronic acid. *Drugs*, **61**: 799-805

Chestnut, M.H., Rogers, M.J., Watts, D.J., Xiong, X., Russell, R.G.G., Ebetino, F.H., Grosik, T.L., Finch, J.L., Amburgey, J.S., and Ibbotson, K.J., (1995)

Cellular uptake of bisphosphonates: localisation using fluorescently-labelled alendronate. *Bone*, **17**: 599

Chlebowski, R.T., (2001)

Factors influencing the role of bisphosphonates in breast cancer management. *Semin Oncol*, **28**: 42-8.

Clark, E.A., Golub, T.R., Lander, E.S. and Hynes, R.O., (2000)

Genomic analysis of metastasis reveals an essential role for RhoC. *Nature*, **406**: 532-5.

Coleman, R.E., (2001)

Should bisphosphonates be the treatment of choice for metastatic bone disease? *Semin Oncol*, **28**: 35-41.

Coleman, R.E. and Seaman, J.J., (2001)

The role of zoledronic acid in cancer: clinical studies in the treatment and prevention of bone metastases. *Semin Oncol*, **28**: 11-6.

Coxon, F.P., Benford, H.L., Russell, R.G. and Rogers, M.J., (1998)

Protein synthesis is required for caspase activation and induction of apoptosis by bisphosphonate drugs. *Mol Pharmacol*, **54**: 631-8.

Coxon, F.P., Helfrich, M.H., Van't Hof, R., Sebti, S., Ralston, S.H., Hamilton, A. and Rogers, M.J., (2000)

Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298. *J Bone Miner Res*, **15**: 1467-76.

Cruz, J.C., Alsina, M., Craig, F., Yoneda, T., Anderson, J.L., Dallas, M. and Roodman, G.D., (2001)

Ibandronate decreases bone disease development and osteoclast stimulatory activity in an in vivo model of human myeloma. *Exp Hematol*, **29**: 441-7.

Daley-Yates, P.T., Dodwell, D.J., Pongchaidecha, M., Coleman, R.E. and Howell, A., (1991)

The clearance and bioavailability of pamidronate in patients with breast cancer and bone metastases. *Calcif Tissue Int*, **49**: 433-5.

Darzynkiewicz, Z., Gong, J., Traganos, F., (1994)

Analysis of DNA content and cyclin protein expression in studies of DNA ploidy, growth fraction, lymphocyte stimulation, and the cell cycle. *Methods Cell Biol*, **41**:421-35

Das, H., Wang, L., Kamath, A. and Bukowski, J.F., (2001)

Vgamma2Vdelta2 T-cell receptor-mediated recognition of aminobisphosphonates. *Blood*, **98**: 1616-8.

David, P. and Baron, R., (1995)

The vacuolar H⁺-ATPase: a potential target for drug development in bone diseases. *Exp Opin Invest Drugs*, **4**: 725-39

de Groen, P.C., Lubbe, D.F., Hirsch, L.J., Daifotis, A., Stephenson, W., Freedholm, D., Pryor-Tillotson, S., Seleznick, M.J., Pinkas, H. and Wang, K.K., (1996)

Esophagitis associated with the use of alendronate. *N Engl J Med*, **335**: 1016-21.

Derenne, S., Amiot, M., Barille, S., Collette, M., Robillard, N., Berthaud, P., Harousseau, J.L. and Bataille, R., (1999)

Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment. *J Bone Miner Res*, **14**: 2048-56.

des Grottes, J.M., Dumon, J.C. and Body, J.J., (2001)

Hypercalcaemia of melanoma: incidence, pathogenesis and therapy with bisphosphonates. *Melanoma Res*, **11**: 477-82.

Diel, I., Lichinitser, M. and Body, J., (1999)

Improvement of bone pain, quality of life and survival time of breast cancer patients with metastatic bone disease. *Eur J Cancer*, **35**: 269

Diel, I.J., (2000)

Antitumour effects of bisphosphonates: first evidence and possible mechanisms. *Drugs*, **59**: 391-9.

Diel, I.J., (2001)

Bisphosphonates in the prevention of bone metastases: current evidence. *Semin Oncol*, **28**: 75-80.

Diel, I.J. and Mundy, G.R., (2000)

Bisphosphonates in the adjuvant treatment of cancer: experimental evidence and first clinical results. International Bone and Cancer Study Group (IBCG). *Br J Cancer*, **82**: 1381-6.

Diel, I.J., Solomayer, E.F. and Bastert, G., (2000)

Bisphosphonates and the prevention of metastasis: first evidences from preclinical and clinical studies. *Cancer*, **88**: 3080-8.

Dunford, J.E., Thompson, K., Coxon, F.P., Luckman, S.P., Hahn, F.M., Poulter, C.D., Ebetino, F.H. and Rogers, M.J., (2001)

Structure-activity relationships for inhibition of farnesyl diphosphate synthase *in vitro* and inhibition of bone resorption *in vivo* by nitrogen- containing bisphosphonates. *J Pharmacol Exp Ther*, **296**: 235-42.

Ebetino, F., Francis, M., Rogers, M. and Russell, R., (1998)

Mechanisms of action of etidronate and other bisphosphonates. *Rev Contemp Pharmacother*, **9**: 233-43

Farthmann, B., Eberle, J., Krasagakis, K., Gstottner, M., Wang, N., Bisson, S. and Orfanos C.E., (1998)

RT-PCR for tyrosinase-mRNA-positive cells in peripheral blood: evaluation strategy and correlation with known prognostic markers in 123 melanoma patients. *Invest Dermatol*, **110**(3):263-7

Felix, R., Guenther, H.L. and Fleisch, H., (1984)

The subcellular distribution of [¹⁴C]dichloromethylenebisphosphonate and [¹⁴C]1-hydroxyethylidene-1,1-bisphosphonate in cultured calvaria cells. *Calcif Tissue Int*, **36**: 108-13.

Fisher, J.E., Rodan, G.A. and Reszka, A.A., (2000)

In vivo effects of bisphosphonates on the osteoclast mevalonate pathway. *Endocrinology*, **141**: 4793-6.

Fisher, J.E., Rogers, M.J., Halasy, J.M., Luckman, S.P., Hughes, D.E., Masarachia, P.J., Wesolowski, G., Russell, R.G., Rodan, G.A. and Reszka, A.A., (1999)

Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation *in vitro*. *Proc Natl Acad Sci U S A*, **96**: 133-8.

Fleisch, H., (2001)

Zoledronic acid: an evolving role in the treatment of cancer patients with bone disease. *Semin Oncol*, **28**: 45-7.

Folkman, J., (1995)

Angiogenesis in cancer, vascular, rheumatoid and other disease. *Nat Med*, **1**: 27-31.

Folkman, J., (1995)

Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. *N Engl J Med*, **333**: 1757-63.

Fritz, G., Just, I. and Kaina, B., (1999)

Rho GTPases are over-expressed in human tumors. *Int J Cancer*, **81**: 682-7.

Fromigue, O., Lagneaux, L. and Body, J.J., (2000)

Bisphosphonates induce breast cancer cell death *in vitro*. *J Bone Miner Res*, **15**: 2211-21.

Gertz, B.J., Holland, S.D., Kline, W.F., Matuszewski, B.K., Freeman, A., Quan, H., Lasseter, K.C., Mucklow, J.C. and Porras, A.G., (1995)

Studies of the oral bioavailability of alendronate. *Clin Pharmacol Ther*, **58**: 288-98.

Gillies, R.J., Didier, N. and Denton, M., (1986)

Determination of cell number in monolayer cultures. *Anal Biochem*, **159**: 109-13.

Graham, D.Y. and Malaty, H.M., (1999)

Alendronate gastric ulcers. *Aliment Pharmacol Ther*, **13**: 515-9.

Green, J.R., (2001)

Chemical and biological prerequisites for novel bisphosphonate molecules: results of comparative preclinical studies. *Semin Oncol*, **28**: 4-10.

Green, J.R., Muller, K. and Jaeggi, K.A., (1994)

Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound. *J Bone Miner Res*, **9**: 745-51.

Halasy-Nagy, J.M., Rodan, G.A. and Reszka, A.A., (2001)

Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis. *Bone*, **29**: 553-9.

Hall, D.G. and Stoica, G., (1994)

Effect of the bisphosphonate risedronate on bone metastases in a rat mammary adenocarcinoma model system. *J Bone Miner Res*, **9**: 221-30.

Hillner, B.E., Ingle, J.N., Berenson, J.R., Janjan, N.A., Albain, K.S., Lipton, A., Yee, G., Biermann, J.S., Chlebowski, R.T. and Pfister, D.G., (2000)

American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel. *J Clin Oncol*, **18**: 1378-91.

Hiraga T., Williams P. J., Mundy G. R. and Yoneda T., (2001)

The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases. *Cancer Res*, **61**: 4418-24.

Hoffman, A., Stepensky, D., Ezra, A., Van Gelder, J.M. and Golomb, G., (2001)

Mode of administration-dependent pharmacokinetics of bisphosphonates and bioavailability determination. *Int J Pharm*, **220**: 1-11.

Jagdev, S.P., Coleman, R.E., Shipman, C.M., Rostami, H.A. and Croucher, P.I., (2001)

The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. *Br J Cancer*, **84**: 1126-34.

Jagdev, S.P., Purohit, P., Heatley, S., Herling, C. and Coleman, R.E., (2001)

Comparison of the effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease. *Ann Oncol*, **12**: 1433-8.

Janner, M., Muhlbauer, R.C. and Fleisch, H., (1991)

Sodium EDTA enhances intestinal absorption of two bisphosphonates. *Calcif Tissue Int*, **49**: 280-3.

Jansen, B., Schlagbauer-Wadl, H., Brown, B.D., Bryan, R.N., van Elsas, A., Muller, M., Wolff, K., Eichler, H.G. and Pehamberger, H., (1998)

bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. *Nat Med*, **4**: 232-4.

Jung A, Bisaz S, Fleish H, (1973)

The binding of pyrophosphate and two diphosphonates by hydroxyapatite crystals. *Calcif Tissue Res*, **11**: 269-80

Kim, C.J., Reintgen, D.S. and Balch, C.M., (2002)

The new melanoma staging system. *Cancer Control*, **9**: 9-15.

Klein, B.Y., Ben-Bassat, H., Breuer, E., Solomon, V. and Golomb, G., (1998)

Structurally different bisphosphonates exert opposing effects on alkaline phosphatase and mineralization in marrow osteoprogenitors. *J Cell Biochem*, **68**: 186-94.

Kostenuik, P.J., Orr, F.W., Suyama, K. and Singh, G., (1993)

Increased growth rate and tumor burden of spontaneously metastatic Walker 256 cancer cells in the skeleton of bisphosphonate-treated rats. *Cancer Res*, **53**: 5452-7.

Kunzmann, V., Bauer, E., Feurle, J., Weissinger, F., Tony, H.P. and Wilhelm, M., (2000)

Stimulation of gamma delta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. *Blood*, **96**: 384-92.

Laemmli, U.K., (1970)

Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature*, **227**: 680-5.

Lee, M.V., Fong, E.M., Singer, F.R. and Guenette, R.S., (2001)

Bisphosphonate treatment inhibits the growth of prostate cancer cells. *Cancer Res*, **61**: 2602-8.

Lin, J.H., (1996)

Bisphosphonates: a review of their pharmacokinetic properties. *Bone*, **18**: 75-85.

Luckman, S.P., Coxon, F.P., Ebetino, F.H., Russell, R.G. and Rogers, M.J., (1998)

Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure- activity relationships in J774 macrophages. *J Bone Miner Res*, **13**: 1668-78.

Luckman, S.P., Hughes, D.E., Coxon, F.P., Graham, R., Russell, G. and Rogers, M.J., (1998)

Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. *J Bone Miner Res*, **13**: 581-9.

Lufkin, E.G., Argueta, R., Whitaker, M.D., Cameron, A.L., Wong, V.H., Egan, K.S., O'Fallon, W.M. and Riggs, B.L., (1994)

Pamidronate: an unrecognized problem in gastrointestinal tolerability. *Osteoporos Int*, **4**: 320-2.

Mackie, P.S., Fisher, J.L., Zhou, H. and Choong, P.F., (2001)

Bisphosphonates regulate cell growth and gene expression in the UMR 106- 01 clonal rat osteosarcoma cell line. *Br J Cancer*, **84**: 951-8.

Martin, M.B., Arnold, W., Heath, H.T., 3rd, Urbina, J.A. and Oldfield, E., (1999)

Nitrogen-containing bisphosphonates as carbocation transition state analogs for isoprenoid biosynthesis. *Biochem Biophys Res Commun*, **263**: 754-8.

Matozaki, T., Nakanishi, H. and Takai, Y., (2000)

Small G-protein networks: their crosstalk and signal cascades. *Cell Signal*, **12**: 515-24.

Müller, M., Green, J.R., Fabbro, D.,(1996)

The bisphosphonate pamidronate inhibits the growth of a murine myeloma cell line in syngeneic mice [abstract]. *Blood*, **88**:2333

Müller-Wieprecht, V., Riebeling, C., Stooss, A., Orfanos, C.E., Geilen, C.C., (2000)

Bcl-2 transfected HaCaT keratinocytes resist apoptotic signals of ceramides, tumor necrosis factor α and $1\alpha,25$ -dihydroxyvitamin D₃. *Arch Dermatol Res*, **292**: 455-462

Mundy, G.R., Yoneda, T. and Hiraga, T., (2001)

Preclinical studies with zoledronic acid and other bisphosphonates: impact on the bone microenvironment. *Semin Oncol*, **28**: 35-44.

Naderi, S., Blomhoff, R., Myklebust, J., Smeland, E.B., Erikstein, B., Norum, K.R. and Blomhoff, H.K., (1999)

Lovastatin inhibits G1/S transition of normal human B-Lymphocytes independent of apoptosis. *Exp. Cell Res*. **252**: 144-153

Nestle, F.O., Alijagic, S., Gilliet, M., Sun, Y., Grabbe, S., Dummer, R., Burg, G. and Schadendorf, D., (1998)

Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. *Nat Med*, **4**: 328-32.

Orfanos, C.E. and Garbe, C., (2001)

Therapie der Hautkrankheiten, (2nd edition) *Springer, Berlin*

Padayatty, S.J., Marcelli, M., Shao, T.C. and Cunningham, G.R., (1997)

Lovastatin-induced apoptosis in prostate stromal cells. *J Clin Endocrinol Metab*, **82**: 1434-9.

Paterson, A.H., (2000)

The potential role of bisphosphonates as adjuvant therapy in the prevention of bone metastases. *Cancer*, **88**: 3038-46.

Paterson, A.H., (2001)

Adjuvant bisphosphonate therapy: the future. *Semin Oncol*, **28**: 81-5.

Perez, E.A., (2001)

Metastatic bone disease in breast cancer: the patient's perspective. *Semin Oncol*, **28**: 60-3.

Perez-Sala, D., Collado-Escobar, D. and Mollinedo, F., (1995)

Intracellular alkalization suppresses lovastatin-induced apoptosis in HL-60 cells through the inactivation of a pH-dependent endonuclease. *J Biol Chem*, **270**: 6235-42.

Powles, T.J., McCloskey, E., Paterson, A.H., Ashley, S., Tidy, V.A., Nevantaus, A., Rosenqvist, K. and Kanis, J., (1998)

Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer. *J Natl Cancer Inst*, **90**: 704-8.

Pruitt, K. and Der, C.J., (2001)

Ras and Rho regulation of the cell cycle and oncogenesis. *Cancer Lett*, **171**: 1-10.

Raisova, M., Hossini, A.M., Eberle, J., Riebeling, C., Wieder, T., Sturm, I., Daniel, P.T., Orfanos, C.E. and Geilen, C.C., (2001)

The Bax/Bcl-2 ratio determines the susceptibility of human melanoma cells to CD95/Fas-mediated apoptosis. *J Invest Dermatol*, **117**: 333-40.

Raisova, M., Goltz, G., Bektas, M., Bielawska, A., Riebeling, C., Hossini, A.M., Eberle, J., Hannun, Y.A., Orfanos, C.E., Geilen, C.C., (2002)

Bcl-2 overexpression prevents apoptosis induced by ceramidase inhibitors in malignant melanoma and HaCaT keratinocytes. *FEBS Lett*, **516(1-3)**: 47-52.

Reinholz, G.G., Getz, B., Pederson, L., Sanders, E.S., Subramaniam, M., Ingle, J.N. and Spelsberg, T.C., (2000)

Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts. *Cancer Res*, **60**: 6001-7.

Reszka, A.A., Halasy-Nagy, J. and Rodan, G.A., (2001)

Nitrogen-bisphosphonates block retinoblastoma phosphorylation and cell growth by inhibiting the cholesterol biosynthetic pathway in a keratinocyte model for esophageal irritation. *Mol Pharmacol*, **59**: 193-202.

Reszka, A.A., Halasy-Nagy, J.M., Masarachia, P.J. and Rodan, G.A., (1999)

Bisphosphonates act directly on the osteoclast to induce caspase cleavage of mst1 kinase during apoptosis. A link between inhibition of the mevalonate pathway and regulation of an apoptosis-promoting kinase. *J Biol Chem*, **274**: 34967-73.

Reuter, C.W., Morgan, M.A. and Bergmann, L., (2000)

Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies? *Blood*, **96**: 1655-69.

Riebeling, C., Forsea, AM., Raisova, M., Orfanos, C. E., Geilen, C.C., (2002)

The bisphosphonate pamidronate induces apoptosis in human melanoma cells *in vitro*. *British J Cancer*, (in print)

Rodan, G.A., Sedor, J.G. and Balena, R., (1993)

Preclinical pharmacology of alendronate. *Osteoporos Int*, **3**: S7-12.

Rogers, M.J., Brown, R.J., Hodkin, V., Blackburn, G.M., Russell, R.G. and Watts, D.J., (1996)

Bisphosphonates are incorporated into adenine nucleotides by human aminoacyl-tRNA synthetase enzymes. *Biochem Biophys Res Commun*, **224**: 863-9.

Rogers, M.J., Frith, J.C., Luckman, S.P., Coxon, F.P., Benford, H.L., Monkkonen, J., Auriola, S., Chilton, K.M. and Russell, R.G., (1999)

Molecular mechanisms of action of bisphosphonates. *Bone*, **24**: 73S-79S.

Rogers, M.J., Gordon, S., Benford, H.L., Coxon, F.P., Luckman, S.P., Monkkonen, J. and Frith, J.C., (2000)

Cellular and molecular mechanisms of action of bisphosphonates. *Cancer*, **88**: 2961-78.

Rogers, M.J., Xiong, X., Brown, R.J., Watts, D.J., Russell, R.G., Bayless, A.V. and Ebetino, F.H., (1995)

Structure-activity relationships of new heterocycle-containing bisphosphonates as inhibitors of bone resorption and as inhibitors of growth of *Dictyostelium discoideum* amoebae. *Mol Pharmacol*, **47**: 398-402.

Russell, R.G. and Rogers, M.J., (1999)

Bisphosphonates: from the laboratory to the clinic and back again. *Bone*, **25**: 97-106.

Russell, R.G., Rogers, M.J., Frith, J.C., Luckman, S.P., Coxon, F.P., Benford, H.L., Croucher, P.I., Shipman, C. and Fleisch, H.A., (1999)

The pharmacology of bisphosphonates and new insights into their mechanisms of action. *J Bone Miner Res*, **14 Suppl 2**: 53-65.

Saarto, T., Blomqvist, C., Virkkunen, P. and Elomaa, I., (2001)

Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. *J Clin Oncol*, **19**: 10-7.

Salomo, M. and Gimsing, P., (2001)

Bisphosphonates and *in vivo* models of multiple myeloma. *Br J Haematol*, **113**: 841-2.

Sasaki, A., Boyce, B.F., Story, B., Wright, K.R., Chapman, M., Boyce, R., Mundy, G.R. and Yoneda, T., (1995)

Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. *Cancer Res*, **55**: 3551-7.

Sasaki, A., Kitamura, K., Alcalde, R.E., Tanaka, T., Suzuki, A., Etoh, Y. and Matsumura, T., (1998)

Effect of a newly developed bisphosphonate, YH529, on osteolytic bone metastases in nude mice. *Int J Cancer*, **77**: 279-85.

Schadendorf, D., Worm, M., Algermissen, B., Kohlmus, C.M. and Czarnetzki, B.M., (1994)

Chemosensitivity testing of human malignant melanoma. A retrospective analysis of clinical response and *in vitro* drug sensitivity. *Cancer*, **73**: 103-8.

Schmidt, A., Rutledge, S.J., Endo, N., Opas, E.E., Tanaka, H., Wesolowski, G., Leu, C.T., Huang, Z., Ramachandaran, C., Rodan, S.B. and Rodan, G.A., (1996)

Protein-tyrosine phosphatase activity regulates osteoclast formation and function: inhibition by alendronate. *Proc Natl Acad Sci U S A*, **93**: 3068-73.

Schneeberger, A., Goos, M., Stingl, G. and Wagner, S.N., (2000)

Management of malignant melanoma: new developments in immune and gene therapy. *Clin Exp Dermatol*, **25**: 509-19.

Seneratne SG, Pirianov G, Mansi JL, Arnett TR and KW, C., (2000)

Bisphosphonates induce apoptosis in human breast cancer cell lines. *British Journal of cancer*, **82**: 1459-68

Shipman, C.M., Croucher, P.I., Russell, R.G., Helfrich, M.H. and Rogers, M.J., (1998)

The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells *in vitro* by inhibiting the mevalonate pathway. *Cancer Res*, **58**: 5294-7.

Shipman, C.M., Rogers, M.J., Apperley, J.F., Russell, R.G. and Croucher, P.I., (1997)

Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. *Br J Haematol*, **98**: 665-72.

Shipman, C.M., Rogers, M.J., Vanderkerken, K., Van Camp, B., Graham, R., Russell, G. and Croucher, P.I., (2000)

Bisphosphonates--mechanisms of action in multiple myeloma. *Acta Oncol*, **39**: 829-35

Shipman, C.M., Vanderkerken, K., Rogers, M.J., Lippitt, J.M., Asosingh, K., Hughes, D.E., Van Camp, B., Russell, R.G. and Croucher, P.I., (2000)

The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma. *Br J Haematol*, **111**: 283-6.

Sietsema, W.K., Ebetino, F.H., Salvagno, A.M. and Bevan, J.A., (1989)

Antiresorptive dose-response relationships across three generations of bisphosphonates. *Drugs Exp Clin Res*, **15**: 389-96

Skobe, M., Hamberg, L.M., Hawighorst, T., Schirner, M., Wolf, G.L., Alitalo, K. and Detmar, M., (2001)

Concurrent induction of lymphangiogenesis, angiogenesis, and macrophage recruitment by vascular endothelial growth factor-C in melanoma. *Am J Pathol*, **159**: 893-903.

Sonnemann, J., Eckervogt, V., Truckenbrod, B., Boos, J., Winkelmann, W. and van Valen, F., (2001)

The bisphosphonate pamidronate is a potent inhibitor of human osteosarcoma cell growth *in vitro*. *Anticancer Drugs*, **12**: 459-65.

Suri, S., Monkkonen, J., Taskinen, M., Pesonen, J., Blank, M.A., Phipps, R.J. and Rogers, M.J., (2001)

Nitrogen-containing bisphosphonates induce apoptosis of Caco-2 cells *in vitro* by inhibiting the mevalonate pathway: a model of bisphosphonate-induced gastrointestinal toxicity. *Bone*, **29**: 336-43.

Takahashi, R., Shimazaki, C., Inaba, T., Okano, A., Hatsuse, M., Okamoto, A., Hirai, H., Ashihara, E. and Nakagawa, M., (2001)

A newly developed bisphosphonate, YM529, is a potent apoptosis inducer of human myeloma cells. *Leuk Res*, **25**: 77-83.

Tassone, P., Forciniti, S., Galea, E., Morrone, G., Turco, M.C., Martinelli, V., Tagliaferri, P. and Venuta, S., (2000)

Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines. *Leukemia*, **14**: 841-4.

Teronen, O., Konttinen, Y.T., Salo, T., Lindqvist, C., Heikkila, P., Laitinen, M. and Sorsa, T., (1999)

[Bisphosphonates inhibit matrix metalloproteinases--a new possible mechanism of action]. *Duodecim*, **115**: 13-5

Thompson, K., Dunford, J.E., Ebetino, F.H. and Rogers, M.J., (2002)

Identification of a bisphosphonate that inhibits isopentenyl diphosphate isomerase and farnesyl diphosphate synthase. *Biochem Biophys Res Commun*, **290**: 869-73.

Towbin, H., Staehelin, T. and Gordon, J., (1979)

Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. *Proc Natl Acad Sci U S A*, **76**: 4350-4.

Tripathy, D., (2001)

Bisphosphonates in oncology: breast cancer and beyond. *Semin Oncol*, **28**: 86-91.

Twiss, I.M., Pas, O., Ramp-Koopmanschap, W., Den Hartigh, J. and Vermeij, P., (1999)

The effects of nitrogen-containing bisphosphonates on human epithelial (Caco-2) cells, an *in vitro* model for intestinal epithelium. *J Bone Miner Res*, **14**: 784-91.

van Beek, E., Hoekstra, M., van de Ruit, M., Lowik, C. and Papapoulos, S., (1994)

Structural requirements for bisphosphonate actions *in vitro*. *J Bone Miner Res*, **9**: 1875-82.

van Beek, E., Pieterman, E., Cohen, L., Lowik, C. and Papapoulos, S., (1999)

Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. *Biochem Biophys Res Commun*, **264**: 108-111.

van Beek, E., Pieterman, E., Cohen, L., Lowik, C. and Papapoulos, S., (1999)

Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies *in vitro* and *in vivo*. *Biochem Biophys Res Commun*, **255**: 491-4.

van Beek, E.R., Lowik, C.W., Ebetino, F.H. and Papapoulos, S.E., (1998)

Binding and antiresorptive properties of heterocycle-containing bisphosphonate analogs: structure-activity relationships. *Bone*, **23**: 437-42.

Van Beek, E.R., Lowik, C.W. and Papapoulos, S.E., (2002)

Bisphosphonates suppress bone resorption by a direct effect on early osteoclast precursors without affecting the osteoclastogenic capacity of osteogenic cells: the role of protein geranylgeranylation in the action of nitrogencontaining bisphosphonates on osteoclast precursors. *Bone*, **30**: 64-70.

van der Pluijm, G., Vloedgraven, H., van Beek, E., van der Wee-Pals, L., Lowik, C. and Papapoulos, S., (1996)

Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices *in vitro*. *J Clin Invest*, **98**: 698-705.

Van Poznak, C., (2001)

How are bisphosphonates used today in breast cancer clinical practice? *Semin Oncol*, **28**: 69-74.

Vasikaran, S.D., (2001)

Bisphosphonates: an overview with special reference to alendronate. *Ann Clin Biochem*, **38**: 608-23.

Vogt, A., Sun, J., Quian, Y., Hamilton, A.D. and Sebti, S.M., (1997)

The geranylgeranyltransferase-I inhibitor GGTI-298 arrests human tumor cells in G0/G1 and induces p21 WAF1/CIP1/SDI1 in a p53-independent manner. *J Biol Chem*. **272**: 108-111

Wieder, T., Orfanos, C.E., Geilen, C.C., (1998)

Induction of ceramide-mediated apoptosis by the anticancer phospholipid analog, hexadecylphosphocholine. *J Biol Chem*, **273(18)**:11025-31.

Zohn, I.M., Campbell, S.L., Khosravi-Far, R., Rossman, K.L. and Der, C.J., (1998)

Rho family proteins and Ras transformation: the RHOad less traveled gets congested. *Oncogene*, **17**: 1415-38.

Zhang, J.H., and Xu, M., (2000)

DNA fragmentation in apoptosis. *Cell Res*, **10(3)**:205-11.